anoth strong quarter demonstr us momentum
address market expans somewhat off-set softer ex
us price headwind off-set volum
libr deck
result momentum-st us strength off-set rel ex-u weak
deliv strong sale vs mse
beat highlight preview estim like
conserv given impli momentum deceler wherea
deliv momentum stabil minimum past
consecut quarter outcom achiev stabl result
preview expect guidanc rais least in-lin
beat deliv well rais
year increas midpoint nearli
quarterli beat rais midpoint vs beat post
us sale vs mse beat impli pt
momentum acceler driven continu traction pharmaci ex-u
sale miss mse momentum deceler driven
part re-ord time slip discuss in-
line mse remain pressur on-going invest manufactur
capac expans although manag reiter expect
improv back-half approach line model
trend margin improv critic continu stock out-performance
expect exit ebit margin vs lrp outlook
demonstr longer term potenti oper leverag
explan ex-u trend pt momentum deceler
unexpect time account part deceler
sale shift howev even adjust time busi
grew q/q pt deceler vs q/q growth
prior two year model q/q growth vs
prior two year driven time shift manag confid direct
sell momentum attribut issu time libr break trend
ex-u quarter look forward addit data point better
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
understand dynam outlook model y/i
guidanc may still prove conserv similar last quarter see
takeaway rais guidanc roughli beat remain
comfort high end updat guidanc still impli pt
momentum deceler season resembl
prior year given upcom rate cut class ii devic discuss
certain pharmaci dme payor contract take
effect trade better access exchang moder
price concess season weaker preced suggest
factor point us revenu
impli pt pt momentum deceler respect note
momentum stabil back half impli upsid
dig deeper price headwind price headwind
increas saw price
headwind expect acceler backhalf
increment price weight driven improv
patient access exchang price concess addit pharmaci
contract broad rate cut class ii devic
updat competit market dynam commentari suggest dexcom
coverag stand vs libr said manag see
signific differ major payor term access coverag
normal next catalyst like libr icgm approv see
expect see stock weak post libr approv assum icgm
design view buy opportun expect libr
derail expans vs share/pric trend share shift
payor dynam worth watch reset competit landscap
go full commerci launch cog one mani
dynam drove enthusiasm ada although manag
specif call sens unit econom could approach libr
cog run rate ada takeaway addit thought
unit econom
bia continu posit pt identifi posit traction
earli given earlier expect approv headwind
competit price pressur left us balanc long term pathway
sale growth becom clear driven on-going roll-out
increas access shift pharmaci channel busi
momentum like continu driver off-set fade hardwar
revenu disrupt pharmaci channel shift libr pt
prior base ev sale line high growth smid
expans vs competit price risk impli polar risk-reward skew
expans vs competit price risk impli polar risk-reward skew
price target reflect ev sale multipl
base case sale in-lin high growth smid
cap devic compani support dcf valuat assum
wacc termin growth rate
ev sale support dcf analysi
ev sale support dcf analysi
expans drive continu inflect penetr rate guardian
libr traction limit prove market expans premium price
sustain libr seen inferior product verili come sooner
expect success non-intens popul verili pbm
distribut drive clear path opm
ev sale support dcf analysi
ev sale support dcf analysi
revenu growth sustain expans outweigh
competit pressur price pressur materi near term
medicar shift pharmaci integr system drive ww growth
juri remain type adopt rate
ev sale support dcf analysi
ev sale support dcf analysi
lower share price pressur limit profit guardian libr
becom competit core medicar user libr disrupt price
model sensor price collaps cgm fail gain traction non-intens
popul verili unabl drive gm expans dme distribut limit
oper leverag path profit becom less clear
continu glucos monitor cgm
secular growth stori ampl room run
see long runway cgm penetr
grow long term
driven product evolut elimin
fingerstick test improv form factor
integr insulin deliveri
technolog leadership
sustain longer term market
becom crowd
near-term price sustain despit
pressur libr lower price point
medicar new patient build
acceler core us growth germani
advantag new competitor
shift pharmaci on-going
risk achiev price
guardian libr competit greater
expect limit new patient start
traction medicar limit
coverag guardian libr come
sooner expect
limit path profit delay failur
pipelin catalyst
million except ep
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
prepaid current asset
properti plant equip net
liabil equiti
account payabl accru liabil
accru payrol relat expens
current portion long-term debt
current portion defer revenu
long-term portion defer revenu
accumul comprehens loss
total liabil equiti
dollar million except per share data
oper
depreci amort
non-cash research develop issuanc common stock
accret amort relat market secur net
amort debt issuanc cost
chang fair valu conting consider
loss dispos equip
chang oper asset liabil
prepaid
account payabl accru liabil
accru payrol relat expens
defer rent liabil
net cash provid oper
invest
purchas available-for-sal market secur
proce matur available-for-sal market secur
purchas properti equip
acquisit net cash acquir
net cash use invest activ
financ
net proce issuanc common stock
issuanc repay debt
repurchas share
net cash use financ activ
begin period
end period
